Biotech Values

[DewDiligence]

>I somehow doubt that Dew ever gave more than a few seconds consideration to such procedures for himself…<

Actually, beachgal, I’ve sampled a few of these treatments—including Botox and Restylane—to have a better idea of the investment appeal of the companies that purvey them. And I talk to “injectors” – the silly-sounding term that the drug companies use to refer to the people who administer the treatments.

Artefill/Artecoll is considered by many injectors to be a loser for the reasons I cited in an earlier post. Many doctors won’t even consider it because of the risk, however modest, of permanent disfigurement.

Moreover, the newer hyaluronic-acid fillers such as Restylane last long enough (6-12 months) that duration is not nearly as big an issue for consumers as it was with the shorter-acting collagen fillers such as the ones sold by IMDC and MNT.

By the way, a little known aspect of Botox is that the potency varies considerably from batch to batch, and this variation is inherent in AGN’s archaic botulinum technology. Regards, Dew